CL2014000604A1 - Compuestos derivados de dihidroquinolina-2-ona, inhibidores de aldosterona sintasa; procedimiento de preparacion; composicion farmaceutica que los comprende; su uso para el tratamiento o profilaxis de enfermedad renal cronica, insuficiencia cardiaca congestiva, hipertension, aldosteronismo primario y sindrome de cushing. - Google Patents

Compuestos derivados de dihidroquinolina-2-ona, inhibidores de aldosterona sintasa; procedimiento de preparacion; composicion farmaceutica que los comprende; su uso para el tratamiento o profilaxis de enfermedad renal cronica, insuficiencia cardiaca congestiva, hipertension, aldosteronismo primario y sindrome de cushing.

Info

Publication number
CL2014000604A1
CL2014000604A1 CL2014000604A CL2014000604A CL2014000604A1 CL 2014000604 A1 CL2014000604 A1 CL 2014000604A1 CL 2014000604 A CL2014000604 A CL 2014000604A CL 2014000604 A CL2014000604 A CL 2014000604A CL 2014000604 A1 CL2014000604 A1 CL 2014000604A1
Authority
CL
Chile
Prior art keywords
dihydroquinoline
prophylaxis
hypertension
pharmaceutical composition
treatment
Prior art date
Application number
CL2014000604A
Other languages
English (en)
Inventor
Peter Mohr
Yongfu Liu
Johannes Aebi
Kurt Amrein
Benoit Hornsperger
Henner Knust
Bernd Kuhn
Hans P Maerki
Alexander V Mayweg
Xuefel Tan
Mingwei Zhou
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of CL2014000604A1 publication Critical patent/CL2014000604A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/38Drugs for disorders of the endocrine system of the suprarenal hormones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/38Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/42Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of mineralocorticosteroids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/06Peri-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10Spiro-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02Silicon compounds
    • C07F7/08Compounds having one or more C—Si linkages
    • C07F7/18Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1804Compounds having Si-O-C linkages

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CL2014000604A 2011-09-15 2014-03-13 Compuestos derivados de dihidroquinolina-2-ona, inhibidores de aldosterona sintasa; procedimiento de preparacion; composicion farmaceutica que los comprende; su uso para el tratamiento o profilaxis de enfermedad renal cronica, insuficiencia cardiaca congestiva, hipertension, aldosteronismo primario y sindrome de cushing. CL2014000604A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN2011079673 2011-09-15

Publications (1)

Publication Number Publication Date
CL2014000604A1 true CL2014000604A1 (es) 2014-10-17

Family

ID=46829775

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2014000604A CL2014000604A1 (es) 2011-09-15 2014-03-13 Compuestos derivados de dihidroquinolina-2-ona, inhibidores de aldosterona sintasa; procedimiento de preparacion; composicion farmaceutica que los comprende; su uso para el tratamiento o profilaxis de enfermedad renal cronica, insuficiencia cardiaca congestiva, hipertension, aldosteronismo primario y sindrome de cushing.

Country Status (33)

Country Link
US (1) US9260408B2 (es)
EP (2) EP2755963B1 (es)
JP (1) JP6012735B2 (es)
KR (1) KR101785143B1 (es)
CN (1) CN103814021B (es)
AR (1) AR087901A1 (es)
AU (1) AU2012307509B2 (es)
BR (1) BR112014006283B1 (es)
CA (1) CA2846785C (es)
CL (1) CL2014000604A1 (es)
CO (1) CO6890099A2 (es)
CR (1) CR20140091A (es)
DK (1) DK2755963T3 (es)
EA (1) EA035757B1 (es)
EC (1) ECSP14013245A (es)
ES (2) ES2763332T3 (es)
HR (1) HRP20192323T1 (es)
HU (1) HUE047771T2 (es)
IL (1) IL231229A0 (es)
LT (1) LT2755963T (es)
MX (1) MX358376B (es)
MY (1) MY169043A (es)
PE (1) PE20141372A1 (es)
PH (1) PH12014500434A1 (es)
PL (1) PL2755963T3 (es)
PT (1) PT2755963T (es)
RS (1) RS59737B1 (es)
SG (1) SG11201400679WA (es)
SI (1) SI2755963T1 (es)
TW (1) TWI462914B (es)
UA (1) UA111626C2 (es)
WO (1) WO2013037779A1 (es)
ZA (1) ZA201401884B (es)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014135561A1 (en) * 2013-03-08 2014-09-12 F. Hoffmann-La Roche Ag New dihydroquinoline-2-one derivatives as aldosterone synthase (cyp1 1 b2 or cyp1 1 b1 ) inhibitors
RU2015138961A (ru) * 2013-03-14 2017-04-18 Ф. Хоффманн-Ля Рош Аг Производные дигидрохинолин-2-она для применения в качестве ингибиторов альдостеронсинтазы
US9682983B2 (en) 2013-03-14 2017-06-20 The Brigham And Women's Hospital, Inc. BMP inhibitors and methods of use thereof
CN105073732B (zh) * 2013-03-14 2017-07-21 豪夫迈·罗氏有限公司 用作醛固酮合酶抑制剂的二氢喹啉‑2‑酮衍生物
WO2014179186A1 (en) * 2013-04-30 2014-11-06 Boehringer Ingelheim International Gmbh Aldosterone synthase inhibitors
SI3004076T1 (sl) * 2013-05-27 2020-02-28 F. Hoffmann-La Roche Ag Novi spojini 3,4-dihidro-2H-izokinolin-1-on in 2,3-dihidro-izoindol-1-on
JP6581970B2 (ja) * 2013-05-27 2019-09-25 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft 新規3,4−ジヒドロ−2h−イソキノリン−1−オン及び2,3−ジヒドロ−イソインドール−1−オン化合物
CN105143205B (zh) * 2013-05-27 2018-02-02 豪夫迈·罗氏有限公司 新的3,4‑二氢‑2h‑异喹啉‑1‑酮和2,3‑二氢‑异吲哚‑1‑酮化合物
WO2014191338A1 (en) * 2013-05-27 2014-12-04 F. Hoffmann-La Roche Ag New 3,4-dihydro-2h-isoquinoline-1-one and 2,3-dihydro-isoindol-1-one compounds
WO2015125858A1 (ja) * 2014-02-24 2015-08-27 日本曹達株式会社 ヘテロアリール化合物およびその用途
WO2015148654A1 (en) * 2014-03-26 2015-10-01 The Brigham And Women's Hospital, Inc. Compositions and methods for inhibiting bmp
MY176401A (en) 2014-04-24 2020-08-05 Mitsubishi Tanabe Pharma Corp Novel disubstituted 1,2,4-triazine compound
WO2016011019A1 (en) 2014-07-15 2016-01-21 The Brigham And Women's Hospital, Inc. Compositions and methods for inhibiting bmp
PE20171057A1 (es) * 2014-10-08 2017-07-21 Hoffmann La Roche Derivados espirodiamina como inhibidores de la aldosterona sintasa
CN106660998B (zh) * 2014-10-31 2019-10-25 豪夫迈·罗氏有限公司 吡唑基-3,4-二氢喹啉-2-酮醛固酮合酶抑制剂
CN106604917B (zh) * 2014-10-31 2020-10-09 豪夫迈·罗氏有限公司 作为醛固酮合酶抑制剂的新型二氢喹啉吡唑基化合物
JP6622300B2 (ja) * 2014-10-31 2019-12-18 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft 新規なジヒドロキノリンピラゾリル化合物
ES2799300T3 (es) 2015-08-31 2020-12-16 Dong A Socio Holdings Co Ltd Compuestos heteroarilo y su uso como fármacos terapéuticos
JP6314196B2 (ja) * 2015-10-22 2018-04-18 田辺三菱製薬株式会社 医薬組成物
EP3381904B1 (en) * 2015-10-23 2021-07-28 Mitsubishi Tanabe Pharma Corporation Novel nitrogen-containing aromatic heterocyclic compound
US10913730B2 (en) 2016-10-10 2021-02-09 Dong-A Socio Holdings Co., Ltd. Heteroaryl compounds and their use as Mer inhibitors
BR112019006571A2 (pt) * 2016-12-08 2019-07-02 F. Hoffmann-La Roche Ag derivados de éter de isoxazolila como gaba a alfa5 pam
JP7530384B2 (ja) 2019-05-01 2024-08-07 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング (r)-(2-メチルオキシラン-2-イル)メチル 4-ブロモベンゼンスルホネート
WO2023063851A1 (en) * 2021-10-13 2023-04-20 «Target Medicals» Limited Liability Company Inhibitors of human aldosterone synthase (cyp11b2)
CA3236890A1 (en) 2021-12-14 2023-06-22 Boehringer Ingelheim International Gmbh Aldosterone synthase inhibitors for treating chronic kidney disease
AU2023378302A1 (en) * 2022-11-10 2025-04-10 «Target Medicals» Limited Liability Company Inhibitors of human aldosterone synthase (cyp11b2)
CN120187713A (zh) * 2022-11-23 2025-06-20 上海翰森生物医药科技有限公司 吡啶多环类化合物抑制剂、及其制备方法和应用
WO2024235165A1 (zh) * 2023-05-12 2024-11-21 南京明德新药研发有限公司 含氮杂环类化合物及其应用
TW202535378A (zh) * 2023-12-22 2025-09-16 大陸商上海翊石醫藥科技有限公司 一種芳雜環化合物及其製備方法和應用
CN121135736A (zh) * 2024-03-01 2025-12-16 浙江扬厉医药技术有限公司 吡喃并吡啶类化合物、其制备方法、药物组合物及应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8334282D0 (en) * 1983-12-22 1984-02-01 Pfizer Ltd Quinolone inotropic agents
PT79699B (en) * 1983-12-22 1986-12-10 Pfizer Process for preparing quinolone inotropic agents
CN85100796A (zh) * 1985-04-01 1986-10-01 辉瑞公司 喹啉酮衍生物的制备方法
FR2580646A1 (fr) * 1985-04-19 1986-10-24 Synthelabo Derives de 2(1h)-quinolinone, leur preparation et leur application en therapeutique
WO2006113432A2 (en) 2005-04-14 2006-10-26 Smithkline Beecham Corporation Compounds, compositions and methods
DE102008022221A1 (de) * 2008-05-06 2009-11-12 Universität des Saarlandes Inhibitoren der humanen Aldosteronsynthase CYP11B2
WO2010130773A2 (en) 2009-05-15 2010-11-18 Novartis Ag Benzoxazolone derivatives as aldosterone symthase inhibitors
HRP20140371T1 (hr) 2009-05-15 2014-05-23 Novartis Ag Arilpiridini kao inhibitori sinteze aldosterona
US8541404B2 (en) 2009-11-09 2013-09-24 Elexopharm Gmbh Inhibitors of the human aldosterone synthase CYP11B2

Also Published As

Publication number Publication date
ES3016782T3 (en) 2025-05-09
RS59737B1 (sr) 2020-02-28
AR087901A1 (es) 2014-04-23
HUE047771T2 (hu) 2020-05-28
PE20141372A1 (es) 2014-10-13
CA2846785C (en) 2020-09-22
PH12014500434A1 (en) 2017-04-19
SG11201400679WA (en) 2014-04-28
EA035757B1 (ru) 2020-08-05
PL2755963T3 (pl) 2020-07-27
CO6890099A2 (es) 2014-03-10
AU2012307509A1 (en) 2014-03-13
CN103814021B (zh) 2016-12-21
HRP20192323T1 (hr) 2020-03-20
KR101785143B1 (ko) 2017-10-12
LT2755963T (lt) 2020-01-27
CA2846785A1 (en) 2013-03-21
TWI462914B (zh) 2014-12-01
ES2763332T3 (es) 2020-05-28
EP2755963A1 (en) 2014-07-23
EA201490596A1 (ru) 2014-07-30
KR20140067121A (ko) 2014-06-03
MX358376B (es) 2018-08-16
US20130072679A1 (en) 2013-03-21
JP2014527077A (ja) 2014-10-09
CN103814021A (zh) 2014-05-21
IL231229A0 (en) 2014-04-30
CR20140091A (es) 2014-06-03
EP3653618B1 (en) 2025-01-08
WO2013037779A1 (en) 2013-03-21
JP6012735B2 (ja) 2016-10-25
NZ621599A (en) 2016-07-29
ZA201401884B (en) 2019-11-27
EP2755963B1 (en) 2019-10-30
EP3653618A1 (en) 2020-05-20
UA111626C2 (uk) 2016-05-25
ECSP14013245A (es) 2014-07-31
MX2014002770A (es) 2014-06-05
BR112014006283A2 (pt) 2017-04-11
US9260408B2 (en) 2016-02-16
MY169043A (en) 2019-02-07
DK2755963T3 (da) 2020-01-13
AU2012307509B2 (en) 2017-06-29
TW201315724A (zh) 2013-04-16
SI2755963T1 (sl) 2020-01-31
BR112014006283B1 (pt) 2021-11-03
PT2755963T (pt) 2020-01-10

Similar Documents

Publication Publication Date Title
CL2014000604A1 (es) Compuestos derivados de dihidroquinolina-2-ona, inhibidores de aldosterona sintasa; procedimiento de preparacion; composicion farmaceutica que los comprende; su uso para el tratamiento o profilaxis de enfermedad renal cronica, insuficiencia cardiaca congestiva, hipertension, aldosteronismo primario y sindrome de cushing.
CL2014001389A1 (es) Compuestos derivados biciclicos de dihidroisoquinolin-1-ona; proceso de obtencion; composicion faramceutica; y su uso para el tratamiento o la profilaxis de enfermedades renales cronicas, fallo cardiaco congestivo, hipertension, aldosteronismo primario y sindrome de cushing.
EA201790765A1 (ru) Производные спиродиамина в качестве ингибиторов альдостерон-синтазы
CL2014000543A1 (es) Compuestos derivados de imidazopiridazinas sustituidas con amino, inhibidores de la quinasa ,mknk2; metodo de preparacion; compuestos intermediarios y su uso; composicion farmaceutica; combinacion farmaceutica; y su uso para el tratamiento del cancer.
WO2012122383A3 (en) Pi3 kinase inhibitors and uses thereof
CL2013001600A1 (es) Compuestos derivados de acidos 1-bencilcicloalquilcarboxilicos sustituidos; procedimiento de preparacion de dichos compuestos; medicamento que los contiene; y su uso para el tratamiento y/o la prevencion de insuficiencia cardiaca, angina pectoris, hipertonia, afecciones tromboembolicas, insuficiencia renal, entre otras.
EA201591420A1 (ru) Гетероарильные соединения и их применение
LTPA2019507I1 (lt) Farmacinė kompozicija, apimanti nenukleozidinį atvirkštinės transkriptazės inhibitorių
CL2014001779A1 (es) Compuestos derivados de pirimidinas y triazinas fusionadas sustituidas; procedimiento de preparacion; composicion farmaceutica y su uso en el tratamiento y/o prevencion de insuficiencia cardiaca, angina de pecho, hipertension, entre otras enfermedades.
CL2012003415A1 (es) Compuestos derivados de 2-oxo-piperidina y 1,1-dioxido-tiazina, inhibidores de mdm2; composicion farmaceutica que los comprende; y su uso para el tratamiento del cancer .
DK2242750T3 (da) Konformationelt begrænsede biphenyl-derivater til anvendelse som hepatitis C-virusinhibitorer
EA201891024A1 (ru) Соединения-ингибиторы tank-связывающей киназы
CL2013001338A1 (es) Compuestos derivados de benzotieno-piridinas sustituidas, inhibidores de la replicacion del vih; composicion farmaceutica que los comprende; combinacion farmaceutica; kit farmaceutico; y su uso para el tratamiento del vih.
CL2015001279A1 (es) Compuestos derivados de piridina, inhibidores del transportador de uratos urat 1; composicion farmaceutica que los comprende; uso para el tratamiento o prevencion de enfermedades tales como gota, hiperuricemia, hipertensión, enfermedades renales, entre otras.
EA201492223A1 (ru) Новые диазаспироциклоалканы и азаспироциклоалканы
CL2014000459A1 (es) Compuestos derivados de heterociclos biciclicos con nitrogeno; composicion farmaceutica; uso para tratar la hipertension arterial pulmonar.
CL2014000504A1 (es) Compuestos derivados de pirimidinas condensadas sustituidas; procedimiento de preparacion; composicion farmaceutica; y uso en el tratamiento y/o prevencion de la insuficiencia cardiaca, angina de pecho, hipertension, entre otras enfermedades.
DK3632919T3 (da) Farmaceutiske sammensætninger omfattende imidazothiadiazol- og imidazopyrazinderivater som proteaseaktiverede receptor 4-(par4)- hæmmere til behandling af blodpladeaggregering
CL2013000104A1 (es) Compuestos derivados de heterociclicos nitrogenados sustituidos, agonistas del receptor ip; composicion farmaceutica; combinación farmaceutica; y uso para el tratamiento de la hipertension arterial pulmonar.
EA201290642A1 (ru) Соединения и способы
DK2455374T3 (da) Fremgangsmåde til fremstillingen af forbindelser der kan anvendes som inhibitorer af SGLT
CL2014003031A1 (es) Compuestos derivados de uracilo sustituidos biciclicamente; procedimiento de preparacion; composicion farmaceutica; uso para tratar y/o prevenir insuficiencia cardiaca, hipertension pulmonar, epoc, asma, nefropatia, entre otras.
CL2013001141A1 (es) Compuestos derivados de heterociclos condensados, inhibidores del virus de la hepatitis c; composicion farmaceutica que los contiene; y su uso para el tratamiento de la infeccion por el virus de la hepatitis c.
CL2014000849A1 (es) Compuestos derivados de benzilindazoles sustituido, inhibidores de la quinasa bub1; procedimiento de fabricacion; composicion farmaceutica; combinacion farmaceutica; y su uso en el tratamiento de enfermedades hiperproliferativas.
CL2012002716A1 (es) Uso de un compuesto inhibidores de dgat1 porque es útil en la prevención, demora del progreso o el tratamiento de una enfermedad o condición seleccionada a partir de quilomicronemia, síndrome de quilomicronemia familiar e hiperlipoproteinemia tipo v; un compuesto derivado de heteroarilo sustituido; composición farmacéutica.